ClinicalTrials.gg
CompletedNCT03227419SUNSTARUpdated Nov 6, 2026

Abatacept vs Tocilizumab for the Treatment of RA in TNF Alpha Inhibitor Inadequate Responders

A Phase 4 interventional study of Tocilizumab Prefilled Syringe and Abatacept Prefilled Syringe in Arthritis, Rheumatoid, sponsored by Lille Catholic University. Completed at 26 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by Lille Catholic University · Phase 4, Interventional, and Treatment

How we know

Updated Nov 6, 2026Now CompletedPrimary completion moved+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
224
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 110 studies testing tocilizumab in Arthritis, Rheumatoid — 5 open to participants now, 5 under way, none of them phase 3. tocilizumab · Arthritis, Rheumatoid.

Enrollment
29th of 110
224 · median 97
Started
2018
with 4 others
Phase 4
32 of 110
2 open now
Registered
97th of 110
by date

Among the 110 studies testing tocilizumab in Arthritis, Rheumatoid, this one is the 29th largest by enrollment, is one of 5 that started in 2018, is one of 32 in phase 4, and was the 97th registered.

Arthritis, Rheumatoid

3,339 studies on the registry are indexed under Arthritis, Rheumatoid; 446 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

5 of the 110 studies testing tocilizumab in Arthritis, Rheumatoid are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About tocilizumab

tocilizumab: first FDA approval 2010 (ACTEMRA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 293 Arthritis, Rheumatoid studies recruiting now, 151 (52%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 110 studies testing tocilizumab in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

Rheumatoid arthritis (RA) is the most common inflammatory rheumatoid disease in France, affecting 0.3% of the general population. Without effective treatment, the persistent inflammation causes invalidating pain and joint destruction, leading to major functional disability.

Biological agents have been proposed for patients with RA who have the most severe form of the disease and that are inadequate responder patients to conventional synthetic Disease-modifying antirheumatic drugs (csDMARDs). TNF inhibitors (TNFi) are historically proposed as the first biological DAMRD for inadequate responder patients to csDMARDs. A diverse therapeutic arsenal has become available in recent years with the development of non-anti-TNFα drugs whose mechanisms of action are different from the classical TNFi. This new biotherapy class includes tocilizumab and abatacept, two drugs recently available for subcutaneous administration that enables ambulatory care for patients who would otherwise require repeated in-hospital care.

The role of these new treatments in the therapeutic strategy has been emphasized by studies that demonstrated their efficacy as first-line treatments. However, in clinical practice, TNFi remain the most common first-line treatment for the majority of patients, non-anti-TNFα biological agents being reserved for inadequate responder patients.

In second line, several studies have investigated therapeutic strategies for inadequate responder patients to TNFi. Current data suggest that it could be wise to change the therapeutic target after failure of a first-line treatment with TNFi.

Data about the comparative efficacy of different biologics proposed after failure of a first-line treatment with TNFi are in progress. Meta-analyses from registries and academic trials conducted in France and The Netherlands suggest that non-anti-TNFα agents would have equivalent or superior efficacy compared with a second TNFi. This finding suggests clinicians to switch for an alternate therapeutic target after failure of a first-line TNFi.

Data comparing different non-anti-TNFα biologics in inadequate responder patients to TNFi are scare. Industrial trials have demonstrated sustained biological efficacy of non-anti-TNFα biologics after failure of a TNFi. However, there is very little solid data on the direct comparison between them.

Read the detailed description

Rheumatoid arthritis (RA) is the most common inflammatory rheumatoid disease in France, affecting 0.3% of the general population. Without effective treatment, the persistent inflammation causes invalidating pain and joint destruction, leading to major functional disability as well as progressive structural damage resulting in major joint deformity.

Biologic agents are taking on an increasingly important role in the management of patients with an inadequate response to conventional synthetic disease modifying anti-rheumatic drugs (csDMARDs).

Biological DMARD (bDMARD) therapy consists in the use of monoclonal antibodies or fusion proteins, administered intravenously or subcutaneously. The earliest developed biologic agents have been available for more than 15 years. Tumor necrosis factor alpha (TNFα), a pro-inflammatory cytokine, was the first cytokine successfully targeted by a biologic agent for RA treatment. TNF inhibitors (TNFi) are historically proposed as the first bDAMRD for inadequate responder patients to csDMARDs. More recently non-anti-TNFα drugs have emerged, with other biological targets such as interleukin-6 receptor (tocilizumab) or B- (rituximab) and T-lymphocytes (abatacept) that are implicated in the inflammatory response. Initially administered strictly intravenously, these drugs are now available in formulations adapted to subcutaneous administration, which allows ambulatory care for patients who otherwise would require repeated in-hospital care.

National and international guidelines, especially those issued in 2013 by the European League Against Rheumatism (EULAR) and also in 2013 by the French Society of Rheumatology now recommend first-line treatment not only with TNFi but also with non-anti-TNFα biologic agents. However, in routine practice, most clinicians preferably prescribe TNFi for the first-line regimen, reserving non-anti-TNFα drugs to TNFi inadequate responder patients.

There is a growing body of research focusing on first-line biologic agents but there is very little solid data on the direct randomized comparison between them. Actually, all three of the published studies have systematically compared a non-anti-TNFα biomedication versus TNFi (one study with a blinded design and two open studies).

The therapeutic strategy that should be adapted after failure of a TNFi regimen has also been investigated. Those studies favor non-anti-TNF drugs over an alternate TNFi.

There is adequate evidence of the efficacy of the different non-anti-TNFα biologic agents versus placebo after TNFi failure. In other hands, industrial trials have not provided any comparative data between drugs. An academic trial from The Netherlands using medico-economic performance as the primary outcome found no difference in efficacy between abatacept and rituximab (a non-anti-TNFα drug administered exclusively intravenously) after failure of a TNFi. Meta-analyses using data from care networks have not reported any difference between different non-anti-TNFα drugs after failure of a TNFi.

Data from national registries have provided interesting complementary information since in everyday practice these agents are generally used after failure of at least one TNFi. The Danish registry thus suggests that the therapeutic response would be better with tocilizumab than with abatacept. This observation was confirmed by an analysis of French registries data presented at the American College of Rheumatology (ACR) congress in November 2016 showing that tocilizumab exhibits superiority for treatment persistence over 2 years. These results were fully in agreement with the findings of the French ROC trial comparing intravenous administration of a second anti-TNFα drug versus a non-anti-TNFα agent after failure of an anti-TNFα drug that suggested a superiority of tocilizumab over abatacept in the subgroup of patients given a non-anti-TNFα agent. A recent Bayesian network meta-analysis showed better efficacy in the non-anti-TNFα groups for ACR20 in patients who responded insufficiently to an anti-TNFα.

Subcutaneous formulations have been recently developed for both tocilizumab and abatacept. Subcutaneous administration is important because it enables ambulatory care for a substantial number of patients who to date are recurrently hospitalized in day-care units for their intravenous infusions. Excepting specific situations, the subcutaneous formulation will be favored for a large majority of patients because of economic as well as practical considerations. Phase III trials have demonstrated the equivalence of the intravenous versus subcutaneous routes of administration focusing on efficacy and tolerance. The subcutaneous formulation is now also available for routine administration of both tocilizumab and abatacept. Nevertheless, despite large-scale industrial trials on drug equivalence, data issuing from clinical practice suggest a potential difference in the behavior of these two formulations which needs to be explored. Rituximab is apart in the treatment strategy because of its exclusive intravenous administration at spaced intervals and because it is used for specific patient profiles (extra-articular involvement, history of neoplasia, rheumatoid factor (RF) and anti-citrullinated protein antibody (ACPA) positivity). There is no perspective for the development of a subcutaneous formulation of rituximab for RA patients. Furthermore, the routine treatment schedule for rituximab (one-time injections at a mean interval of 9 months) would compromise comparison, especially short-term comparison, with other subcutaneous treatments.

These findings illustrate the need for a new multicentric, prospective, randomized trial designed to demonstrate the superiority of tocilizumab over abatacept in patients exhibiting inadequate response to a first anti-TNFα. A direct comparison of subcutaneous formulation is the need for the promising route of administration for future ambulatory care.

03

Conditions studied

  • Arthritis, Rheumatoid
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • age >18 years
  • RA according to the ACR/EULAR 2010 criteria
  • inadequate response to a subcutaneously administered TNFi defined as moderate to high disease activity (DAS28-ESR>3.2 and CDAI>10) after at least 3 months of treatment with a TNFi
  • beneficiary of the French National Health Insurance Fund
  • signed form
  • for women of childbearing age: effective during treatment period with engagement to continue such contraception for 14 weeks after last administration

Exclusion criteria

Exclusion Criteria:

  • counter-indication for one or other of the two drugs under study
  • prior failure of the TNFi due to intolerance
  • receiving ≥15 mg/day prednisone for more than 4 weeks
  • pregnant or nursing women
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
224 participants (actual)

Study arms

  • Experimental
    Tocilizumab Prefilled Syringe

    Market approval recommendations will be respected. Treatment should be started within 7 days of randomization. The treatment protocol has no specific provision for treatment adaptation. Treatment will be managed in compliance with the marketing approval recommendations and drug labeling described below.

    Drug: Tocilizumab Prefilled Syringe

  • Experimental
    Abatacept Prefilled Syringe

    Market approval recommendations will be respected. Treatment should be started within 7 days of randomization. The treatment protocol has no specific provision for treatment adaptation. Treatment will be managed in compliance with the marketing approval recommendations and drug labeling described below.

    Drug: Abatacept Prefilled Syringe

Interventions

  • DrugTocilizumabStudies of TocilizumabTocilizumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Treatment arm: tocilizumab (RoActemra®): 162 mg weekly a schema for therapeutic adaptation with injection intervals determined according to transaminase levels or blood cell counts (neutropenia, thrombopenia) as recommended by Roche-Chugaï (see table below).

    Also known as: RoActemra

  • DrugAbataceptStudies of AbataceptAbatacept pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Treatment arm: abatacept (Orencia®) 125 mg weekly after an initial dose of 500 mg (body weight \<60kg), 750 mg (body weight between 60 and 100 kg), or 1000 mg (body weight \>100 mg) 24 hours before the first subcutaneous injection.

    Also known as: Orencia

06

What researchers measure

Primary outcomes

  1. Change from baseline to 6 months of the Clinical Disease Activity Index (CDAI)

    The CDAI is a composite score combining clinical items only: Tender 28-joint count, Swollen 28-joint count, Patient Global Disease Activity (PGA), Evaluator"s Global Disease Activity (EGA). This score provides a numerical assessment reflecting disease activity independently of cute phase reactants. It will be measured at baseline and 6 months after inclusion

    Time frame: 6 months

Secondary outcomes

  1. Change from baseline of the disease activity score

    DAS28-ESR and DAS28-CRP: the disease activity score (DAS) is a composite score providing a numerical assessment based on the tender and swollen joint counts, the PGA VAS and the selected acute phase reactant (ESR or CRP).

    Time frame: 3, 6 and 12 months

  2. Change from baseline of the Clinical Disease Activity Index (CDAI)

    The CDAI is a composite score combining clinical items only: Tender 28-joint count, Swollen 28-joint count, Patient Global Disease Activity (PGA), Evaluator"s Global Disease Activity (EGA). This score provides a numerical assessment reflecting disease activity independently of cute phase reactants.

    Time frame: 3 and 12 months

  3. Change from baseline of the SDAI

    the simple disease activity index (SDAI) is a composite score providing a numerical assessment based on the tender and swollen joint count, the PGAVAS, the EGA VAS, and CRP

    Time frame: 3, 6 and 12 months

  4. Change from baseline in HAQ quality-of-life scores

    Time frame: 3, 6 and 12 months

  5. Change from baseline in SF-36 quality-of-life scores

    Time frame: 3, 6 and 12 months

  6. Change from baseline in disease self assessment

    FLARE-RA score

    Time frame: 3, 6 and 12 months

  7. Change from baseline in Patient's Pain Assessment (PPA)

    Time frame: 3, 6 and 12 months

  8. Change from baseline in PGA visual analogic scale (VAS)

    Time frame: 3, 6 and 12 months

  9. Proportion of patients having achieved low disease activity

    Low disease activity (LDA) is defined as DAS28-ESR\<3.2 (LDA-DAS28-ESR) and CDAI\<10 (LDA-CDAI)

    Time frame: 3, 6 and 12 months

  10. Proportion of patients in good or moderate EULAR therapeutic response

    Good or moderate EULAR therapeutic response is defined as at least 0.6-point reduction in DAS28-ESR and final DAS28-ESR\<5.1

    Time frame: 3, 6 and 12 months

  11. Proportion of patients achieving ACR20 response

    ACR20 response correspond to a 20% improvement in the following parameters: number of tender joints; number of swollen joints; 3/5 complementary items (PPA VAS, PGA VAS, EGA VAS, self-administered functional status questionnaire, acute phase reactant)

    Time frame: 3, 6 and 12 months

  12. Proportion of patients achieving ACR50 response

    ACR50 responses correspond respectively to a 50% improvement in the following parameters: number of tender joints; number of swollen joints; 3/5 complementary items (PPA VAS, PGA VAS, EGA VAS, self-administered functional status questionnaire, acute phase reactant)

    Time frame: 3, 6 and 12 months

  13. Proportion of patients achieving ACR70 response

    ACR70 response correspond respectively to a 70% improvement in the following parameters: number of tender joints; number of swollen joints; 3/5 complementary items (PPA VAS, PGA VAS, EGA VAS, self-administered functional status questionnaire, acute phase reactant)

    Time frame: 3, 6 and 12 months

  14. Rates of treatment persistence

    Time frame: 3, 6 and 12 months

  15. Rates of patients presenting at least one adverse events

    Time frame: 3, 6 and 12 months

  16. Rates of treatment withdrawals for intolerance

    Time frame: 3, 6 and 12 months

  17. Rates of treatment withdrawals for intolerance requiring in-hospital care

    Time frame: 3, 6 and 12 months

  18. Rates of cardiovascular events

    Time frame: 3, 6 and 12 months

  19. Rates of perturbation of the lipid profile

    Time frame: 3, 6 and 12 months

  20. Rates of severe infection requiring in-hospital care

    Time frame: 3, 6 and 12 months

  21. Rate of rescue medication use authorized by the protocol and treatment dose of patients achieving treatment persistence

    Time frame: 3, 6 and 12 months

  22. Changes in joint US-Doppler synovitis and Doppler hyperemia grade of the hands and wrists

    Time frame: 6 months

  23. Changes in Sharp score in hands, wrists and feet X-Ray

    Time frame: 12 months

  24. Change in vascular endothelial growth factor (VEGF) levels

    Time frame: At 3 and 6 months

  25. Changes in immunoglobulin (quantitative assay)

    Time frame: 6 months

  26. Changes in interleukin-6 plasma levels

    Time frame: 6 months

07

Study locations

26 sites
08

References and documents

Publications

  • Pascart T, Fautrel B, Gottenberg JE, Ducoulombier V, Richez C, Truchetet ME, Avouac J, Morel J, Basch A, Cormier G; SUNSTAR Study Group; CRI-IMIDIATE Network; Houvenagel E, Mariette X, Norberciak L. Abatacept versus tocilizumab for the treatment of rheumatoid arthritis in TNF inhibitor inadequate responders: study protocol of the SUNSTAR randomised controlled open-label superiority trial. BMJ Open. 2025 Jun 17;15(6):e098298. doi: 10.1136/bmjopen-2024-098298. PubMed 40527572 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2018 to primary completion in Jan 2026, 96 months.

Of 79 non-industry phase 4 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 92. This study's 96 months is above that.

Counting every sponsor, half of 104 studies reached it within 42 months; a quarter within 25 and three quarters within 74.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 6, 2026: primary completion Sep 2024 → Jan 2026 and completion Nov 2024 → Jan 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 19, 2017
First posted
Jul 24, 2017
StartActual
Jan 22, 2018
Primary completionActual
Jan 29, 2026was Sep 2024
CompletionActual
Jan 29, 2026was Nov 2024
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Nov 6, 2026
Sites
3 sites added, 3 sites removed
Show 3 added (3 France)
  • Hôpital Saint-Philibert · Lomme, France
  • CHU de Saint-Etienne · Saint-Etienne, France
  • CHU Saint-Etienne · Saint-Etienne, France
Show 3 removed
  • Hôpital Saint-Philibert · Lomme, France
  • CHU de Saint-Etienne · Saint-Étienne, France
  • CHU Saint-Etienne · Saint-Étienne, France
Nov 6, 2026
Primary completion
Sep 2024→Jan 29, 2026 (actual)
Nov 6, 2026
Study completion
Nov 2024→Jan 29, 2026 (actual)
Nov 6, 2026
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 40527572 ↗
Nov 6, 2026
Secondary outcomes
1 edited
What changed in the outcomes
  • EditedChanges in interleukin-6 serumplasma levelsTime frame: 6 months
Nov 6, 2026
Show all 1 update
  1. Nov 6, 2026
    Recruiting→Completed
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 40527572 ↗
    3 sites added, 3 sites removed
    Show 3 added (3 France)
    • Hôpital Saint-Philibert · Lomme, France
    • CHU de Saint-Etienne · Saint-Etienne, France
    • CHU Saint-Etienne · Saint-Etienne, France
    Show 3 removed
    • Hôpital Saint-Philibert · Lomme, France
    • CHU de Saint-Etienne · Saint-Étienne, France
    • CHU Saint-Etienne · Saint-Étienne, France
    Primary completion Sep 2024→Jan 29, 2026 (now actual)
    Study completion Nov 2024→Jan 29, 2026 (now actual)
    Secondary outcomes 1 edited
    What changed in the outcomes
    • EditedChanges in interleukin-6 serumplasma levelsTime frame: 6 months
    + 3 other changes: verification date, contact details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT03227419
Responsible party
Sponsor
First posted
Jul 24, 2017
Start date
Jan 22, 2018
Primary completion
Jan 29, 2026
Completion
Jan 29, 2026
Last update
Nov 6, 2026

Study contacts

Pascart Tristan, MD
principal investigator · GHICL

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tocilizumab · Abatacept

Start the discussion